ArticleThe breast journal2025
Real-World Efficacy of HLX02-Based Neoadjuvant Therapy in HER2-Positive Breast Cancer: Clinical Insights and Future Directions.
Zhengzhi Zhu, Jing Wang, Shikai Hong, Hong Gao, Jianjun Liu, Kuojun Ren, Shuhan Wang, Shengying Wang, Guoping Sun
Abstract read
In one paragraphArticle in The breast journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Zhengzhi ZhuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0009-0002-2664-0199 Jing WangDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.ORCID 0009-0003-4765-0342 Shikai HongDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Hong GaoDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.ORCID 0009-0007-3066-8334 Jianjun LiuDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Kuojun RenDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.ORCID 0000-0001-6435-6987 Shuhan WangDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Shengying WangDepartment of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Guoping SunDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0002-4325-900X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyTrastuzumabAdultAgedCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansMiddle AgedRetrospective StudiesTreatment OutcomeCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabanti-HER2 therapybreast cancerCDK4/6 inhibitorHER2-positiveHLX02HR-positive
Identifiers
PMID40687942
PMCPMC12271716
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390